patients with SOC and providing expert guidance for skincare use, including gentle cleansers and moisturizers.
AD is a chronic inflammatory skin condition associated with altered immune function and epidermal barrier dysfunction. Racial/ethnic differences in genetic and clinical presentation and sequelae have been reported. In addition, AD-associated xerosis is more stigmatizing in people with SOC. Patients may oscillate between various degrees of severity over time and may even have different levels of severity in various skin areas at any one time. Therefore, the best treatment paradigms reflect a need for a range of products that target these different levels of severity and address specific nuances or unique concerns in populations with SOC.
Treatment of AD in patients with SOC should be proactive, target inflammation, protect the skin barrier, and consider cultural practices. Physicians may recommend prescription treatments and branded moisturizers, but a patient may have specific cultural views and practices that are important to understand in the context of creating a sustainable treatment regimen for that patient. In the SOC populations, clinicians should integrate skincare recommendations and prescription therapies with patient perspectives on skin care norms and priorities in treatment targets.
AD is a chronic inflammatory skin condition associated with altered immune function and epidermal barrier dysfunction. Racial/ethnic differences in genetic and clinical presentation and sequelae have been reported. In addition, AD-associated xerosis is more stigmatizing in people with SOC. Patients may oscillate between various degrees of severity over time and may even have different levels of severity in various skin areas at any one time. Therefore, the best treatment paradigms reflect a need for a range of products that target these different levels of severity and address specific nuances or unique concerns in populations with SOC.
Treatment of AD in patients with SOC should be proactive, target inflammation, protect the skin barrier, and consider cultural practices. Physicians may recommend prescription treatments and branded moisturizers, but a patient may have specific cultural views and practices that are important to understand in the context of creating a sustainable treatment regimen for that patient. In the SOC populations, clinicians should integrate skincare recommendations and prescription therapies with patient perspectives on skin care norms and priorities in treatment targets.
DISCLOSURES
The authors disclose receipt of an unrestricted educational grant
from CeraVe USA for support with the research of this work and
also received consultancy fees for their work on this project. All
the authors developed the manuscript, reviewed it, and agreed
with its content.
REFERENCES
1. Fishbein AB, Silverberg JI, Wilson EJ, Ong PY. Update on atopic dermatitis:
Diagnosis, severity assessment and treatment selection. J Allergy Clin
Immunol Pract. 2020;8(1):91-101. doi: 10.1016/j.jaip.2019.06.044.
2. Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the
United States: data from the 2003 National survey of children's health.
J Invest Dermatol. 2011;131(1):67-73. Doi: 10.1038/jid.2010.251.
3. Janumpally SR, Feldman SR, Gupta AK, Fleischer AB. In the United States,
black and Asian/Pacific Islanders are more likely than whites to seek medical
care for atopic dermatitis. Arch Dematol. 2002;138(5):634-7.
4. Wan J, Oganisian A, Spieker AJ, Hoffstad OJ, Mitra N, Margolis J, et al.
Racial/ethnic variation in use of ambulatory and emergency care for atopic
dermatitis among US children. J Investig Dermatol. 2019;139(9):1906-1913.
PMCID: PMC8320361
5. Kim Y, Blomberg M, Rifs-Shiman SL, Camargo C, Gold DR, Thyssen JP,
et al. Racial/ethnic differences in incidence and persistence of childhood
atopic dermatitis. J Invest Dermatol. 2019;139(4):827-834. Doi: 10.1016/j.
jid.2018.10.029.
6. Bell MA, Whang KA, Thomas J, Aguh C, Kwatra SG. Racial and ethnic
disparities in access to emerging and frontline therapies in common
dermatological conditions: A cross-sectional study. J Natl Med Assoc.
2020;112(6):650-653.
7. Brunner PM, Gutterman-Yassky E. Racial differences in atopic dermatitis.
Ann Allergy Asthma Immunol. 2019;122(5):449-455.
8. Kaufman BP, Guttman-Yassky E, Alexis AF. Atopic dermatitis in diverse racial
and ethnic group-Variations in epidemiology, genetics, clinical presentation,
and treatment. Experi Dermatol. 2018;27:340-357.
9. Margolis DJ, Apter AJ, Gupta J, et al. The persistence of atopic dermatitis
and fillagrin (FLG) mutations in a US longitudinal cohort. J Allergy Clin
Immunol. 2012;130(4):912-7. PMCID: PMC3462287 10. Leung DY. Atopic dermatitis: Age and race do matter! J Allergy Clin Immunol.
2015;136(5):1265-7. DOI: 10.1016/j.jaci.2015.09.011
11. Sanyal RD, Pavel AB, Glickman J, Chan TC, Zheng X, Zhang N, et al. Atopic
dermatitis in African American patients is TH2/TH22-skewed with TH1/TH17
attenuation. Ann Allergy Asthma Immunol. 2019 Jan;122(1):99-110.e6. doi:
10.1016/j.anai.2018.08.024. PMID: 30223113.
12. Alexis AF, Woolery-Lloyd H, Williams K, Andriessen A, Desai S, Han G,
et al. Racial/ethnic variations in skin barrier: Implications for skin care
recommendations in skin of color. J Drugs Dermatol. 2021;20(9):1-7.
doi:10.36849/JDD.6312]
13. McMillan SS, King M, Tully MP. How to use the nominal group and Delphi
techniques. Int J Clin Pharm. 2016;38(3):655-662.
14. Trevelyan EG, Robinson N. (2015). Delphi methodology in health research:
how to do it? Eur J Integrative Med. 2015;7(4):423-428.
15. Lopez Carrera YI, Al Hammadi A, Tallman AM et al. Epidemiology, diagnosis,
and treatment of atopic dermatitis in the developing countries of Asia, Africa,
Latin America, and the Middle East: A review. Dermatol Ther (Heidelb).
2019;9(4):685-705.
16. Mei-Yen Yong A, Tay YK. Atopic dermatitis: racial and ethnic differences.
Dermatol Clin. 2017;35:395–402.[PubMed] [Google Scholar]
17. Shive, Melissa, et al. "Itch as a patient-reported symptom in ambulatory care
visits in the United States." J Am Acad Dermatol. 2013;69(4):550-556.
18. Parronchi P, Largo B. Migrants and allergy: a new view of the atopic march.
Eur Ann Allergy Clin Immunol 2019;51(3):100-114.Lynde CW, Bergman J,
Fiorillo L, et al. Clinical insights about topical treatment of mild-to-moderate
pediatric and adult atopic dermatitis. J Cutan Med Surg. 2019 May/Jun;23(3_
suppl):3S-13S.
19. Rubel D, Thirumoorthy T, Soebaryo RW, Asia-Pacific Consensus Group
for Atopic Dermatitis et al. Consensus guidelines for the management of
atopic dermatitis: an Asia-Pacific perspective. J Dermatol. 2013;40:160–171.
[PubMed] [Google Scholar]
20. Chow S, Seow CS, Dizon MV, et al. Asian Academy of Dermatology and
Venereology. A clinician's reference guide for the management of atopic
dermatitis in Asians. Asia Pac Allergy. 2018;8:e41. [PMC free article][PubMed]
[Google Scholar]
21. Comite Nacional de Dermatologia Atopic dermatitis: national consensus
2013. Arch Argent Pediatr. 2014;112:293–294. [PubMed] [Google Scholar]
22. Wollenberg A, Barbarot S, Bieber T, European Dermatology Forum (EDF) The
European Academy of Dermatology and Venereology (EADV) The European
Academy of Allergy and Clinical Immunology (EAACI) et al. Consensus-based
European guidelines for treatment of atopic eczema (atopic dermatitis) in
adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32:657–682.
23. Wollenberg A, Barbarot S, Bieber T, European Dermatology Forum (EDF) The
European Academy of Dermatology and Venereology (EADV) The European
Academy of Allergy and Clinical Immunology (EAACI) et al. Consensus-based
European guidelines for treatment of atopic eczema (atopic dermatitis) in
adults and children: part II. J Eur Acad Dermatol Venereol. 2018;32:820–878.
24. Dhar S, Parikh D, Rammoorthy R, et al. Treatment guidelines for atopic
dermatitis by ISPD task force 2016 -Part I. Indian J Paediatr Dermatol.
2017;18:174.
25. Dhar S, Parikh D, Srinivas S, et al. Treatment guidelines for atopic dermatitis
by Indian Society for Pediatric Dermatology task force 2016—Part-2: topical
therapies in atopic dermatitis [IJPD symposium] Indian J Paediatr Dermatol.
2017;18:274.
26. Parikh D, Dhar S, Ramamoorthy R, et al. Treatment guidelines for atopic
dermatitis by ISPD task force 2016 [IJPD symposium] Indian J Paediatr
Dermatol. 2018;19:108–115.
27. Saeki H, Nakahara T, Tanaka A, et al. Clinical practice guidelines for the
management of atopic dermatitis 2016. J Dermatol. 2016;43(10):1117-1145.
doi:10.1111/1346-8138.13392
28. Sanchez J, Paez B, Macias A, Olmos C, de Falco A. Atopic dermatitis
guideline. Position paper from the Latin American Society of Allergy, Asthma
and Immunology. Rev Alerg Mex. 2014;61:178–211. [PubMed] [Google
Scholar
29. Centro Nacional de Excelencia Tecnológica. GuÃa de Práctica ClÃnica:
Tratamiento de la Dermatitis Atópica. México: SecretarÃa de Salud; 2014.
http://www.cenetec.salud.gob.mx/descargas/gpc/CatalogoMaestro/IMSS-
706-14-TxDermatitisatopica/706GER.pdf.
30. Rincon-Perez C, Larenas-Linnemann D, Figueroa-Morales MA, et al. Mexican
consensus on the diagnosis and treatment of atopic dermatitis in adolescents
and adults. Rev Alerg Mex. 2018;65(Suppl 2):s8–s88.
31. Reda AM, Elgendi A, Ebraheem AI, et al. A practical algorithm for topical
treatment of atopic dermatitis in the Middle East emphasizing the importance
of sensitive skin areas. J Dermatolog Treat. 2018;30:1–8.
32. Chu C-Y, Lee C-H, Shih IH, et al. Taiwanese Dermatological Association
consensus for the management of atopic dermatitis. Dermatol Sin.
